Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Army
Medtronic
Queensland Health
US Department of Justice
Express Scripts
Deloitte
Cantor Fitzgerald
Federal Trade Commission
Fuji

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202595

« Back to Dashboard

NDA 202595 describes OSELTAMIVIR PHOSPHATE, which is a drug marketed by Amneal Pharms, Macleods Pharms Ltd, Natco Pharma Ltd, Nesher Pharms, and Alvogen Pine Brook, and is included in six NDAs. It is available from ten suppliers. Additional details are available on the OSELTAMIVIR PHOSPHATE profile page.

The generic ingredient in OSELTAMIVIR PHOSPHATE is oseltamivir phosphate. There are seven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

Summary for 202595

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 202595

Suppliers and Packaging for NDA: 202595

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OSELTAMIVIR PHOSPHATE oseltamivir phosphate CAPSULE;ORAL 202595 ANDA Alvogen Inc. 47781-468 47781-468-13 1 BLISTER PACK in 1 CARTON (47781-468-13) > 10 CAPSULE in 1 BLISTER PACK
OSELTAMIVIR PHOSPHATE oseltamivir phosphate CAPSULE;ORAL 202595 ANDA Alvogen Inc. 47781-469 47781-469-13 1 BLISTER PACK in 1 CARTON (47781-469-13) > 10 CAPSULE in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 30MG BASE
Approval Date:Aug 3, 2016TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 45MG BASE
Approval Date:Aug 3, 2016TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 75MG BASE
Approval Date:Aug 3, 2016TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Deloitte
AstraZeneca
Merck
Fish and Richardson
Daiichi Sankyo
Julphar
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot